6,9-dichloro-3,3-dimethyl-1,2,3,4-tetrahydroacridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6,9-dichloro-3,3-dimethyl-1,2,3,4-tetrahydroacridine
• 英文别名: 6,9-dichloro-3,3-dimethyl-2,4-dihydro-1H-acridine
• 化学式: C₁₅H₁₅Cl₂N
• 分子量: 280.197
• InChiKey: OSVJMPTUMXSXMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,9-dichloro-3,3-dimethyl-1,2,3,4-tetrahydroacridine 在 溶剂黄146 作用下， 生成 6-chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one
  参考文献：
  名称：

  Optimization of 1,2,3,4-Tetrahydroacridin-9(10H)-ones as Antimalarials Utilizing Structure–Activity and Structure–Property Relationships

  摘要：

  Antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs) has been known since the 1940s and has garnered more attention with the development of the acridinedione floxacrine (1) in the 1970s and analogues thereof such as WR 243251 (2a) in the 1990s. These compounds failed just prior to clinical development because of suboptimal activity, poor solubility, and rapid induction of parasite resistance. Moreover, detailed structure-activity relationship (SAR) studies of the THA core scaffold were lacking and SPR studies were nonexistent. To improve upon initial findings, several series of 1,2,3,4-tetrahydroacridin-9(10H)-ones were synthesized and tested in a systematic fashion, examining each compound for antimalarial activity, solubility, and permeability. Furthermore, a select set of compounds was chosen for microsomal stability testing to identify physicochemical liabilities of the THA scaffold. Several potent compounds (EC50 < 100 nM) were identified to be active against the clinically relevant isolates W2 and TM90-C2B while possessing good physicochemical properties and little to no cross-resistance.

  DOI：

  10.1021/jm200015a
• 作为产物：
  描述：

  3,3-二甲基环己酮 、 2-氨基-4-氯苯甲酸 在 三氯氧磷 作用下， 反应 2.0h， 以63%的产率得到6,9-dichloro-3,3-dimethyl-1,2,3,4-tetrahydroacridine
  参考文献：
  名称：

  Bistacrine衍生物作为新的有效抗疟药

  摘要：

  与单体相比，连接两个他克林分子导致抗疟原虫的活性大大增加。这一发现促进了单体和二聚他克林衍生物库的合成，以推导结构-活性关系。对氯喹敏感的疟原虫菌株3D7和对氯喹耐药的菌株Dd2最具活性的化合物在纳摩尔浓度范围内显示IC 50值，细胞毒性低，并靶向半胱氨酸蛋白酶falcipain-2，这对寄生虫的生长至关重要。

  DOI：

  10.1016/j.bmc.2016.06.003

文献信息

• Bistacrine derivatives as new potent antimalarials
  作者：Ines Schmidt、Gabriele Pradel、Ludmilla Sologub、Alexandra Golzmann、Che J. Ngwa、Anna Kucharski、Tanja Schirmeister、Ulrike Holzgrabe

  DOI：10.1016/j.bmc.2016.06.003

  日期：2016.8

  Linking two tacrine molecules results in a tremendous increase of activity against Plasmodia in comparison to the monomer. This finding prompted the synthesis of a library of monomeric and dimeric tacrine derivatives in order to derive structure–activity relationships. The most active compounds towards chloroquine sensitive Plasmodium strain 3D7 and chloroquine resistant strain Dd2 show IC50 values

  与单体相比，连接两个他克林分子导致抗疟原虫的活性大大增加。这一发现促进了单体和二聚他克林衍生物库的合成，以推导结构-活性关系。对氯喹敏感的疟原虫菌株3D7和对氯喹耐药的菌株Dd2最具活性的化合物在纳摩尔浓度范围内显示IC 50值，细胞毒性低，并靶向半胱氨酸蛋白酶falcipain-2，这对寄生虫的生长至关重要。
• Optimization of 1,2,3,4-Tetrahydroacridin-9(10<i>H</i>)-ones as Antimalarials Utilizing Structure–Activity and Structure–Property Relationships
  作者：R. Matthew Cross、Jordany R. Maignan、Tina S. Mutka、Lisa Luong、Justin Sargent、Dennis E. Kyle、Roman Manetsch

  DOI：10.1021/jm200015a

  日期：2011.7.14

  Antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs) has been known since the 1940s and has garnered more attention with the development of the acridinedione floxacrine (1) in the 1970s and analogues thereof such as WR 243251 (2a) in the 1990s. These compounds failed just prior to clinical development because of suboptimal activity, poor solubility, and rapid induction of parasite resistance. Moreover, detailed structure-activity relationship (SAR) studies of the THA core scaffold were lacking and SPR studies were nonexistent. To improve upon initial findings, several series of 1,2,3,4-tetrahydroacridin-9(10H)-ones were synthesized and tested in a systematic fashion, examining each compound for antimalarial activity, solubility, and permeability. Furthermore, a select set of compounds was chosen for microsomal stability testing to identify physicochemical liabilities of the THA scaffold. Several potent compounds (EC50 < 100 nM) were identified to be active against the clinically relevant isolates W2 and TM90-C2B while possessing good physicochemical properties and little to no cross-resistance.